The Technical Analyst
Hemcheck Sweden AB (publ) [HEMC.ST]
Exchange: STO Sector: Healthcare Industry: Medical Devices
Hemcheck Sweden AB (publ) Price, Forecast, Insider, Ratings, Fundamentals & Signals
26.11% SEK0.227
America/New_York / 5 des 2023 @ 10:58
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 8.63 mill |
| EPS: | -0.150 |
| P/E: | -1.513 |
| Earnings Date: | N/A |
| SharesOutstanding: | 38.02 mill |
| Avg Daily Volume: | 0.0931 mill |
| RATING 2024-01-02 |
|---|
| B- |
| Neutral |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Neutral | |
| Return On Equity: | Sell | |
| Return On Asset: | Neutral | |
| DE: | Sell | |
| P/E: | Sell | |
| Price To Book: | Neutral |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 2/22 | 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | |
| Revenue | ||||||
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt | n/a | n/a | n/a | n/a | n/a | n/a |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -1.513 | sector: PE 19.76 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -0.03x |
| Company: PE -1.513 | industry: PE 54.10 |
| DISCOUNTED CASH FLOW VALUE |
|---|
| N/A |
| N/A |
| Expected Trading Range (DAY) |
|---|
|
SEK 0.197 - 0.303 ( +/- 21.20%) |
| ATR Model: 14 days |
Live Trading Signals (every 1 min)
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | SEK0.227 (26.11% ) |
| Volume | 0.252 mill |
| Avg. Vol. | 0.0931 mill |
| % of Avg. Vol | 270.34 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For HEMC.ST
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
HEMC.ST
Hemcheck Sweden AB (publ) operates as a medical technology company in Sweden. The company develops and commercializes Helge, which detects hemolysis in blood samples at the point of care. It serves emergency departments in the European Union and the United States. The company was founded in 2010 and is based in Karlstad, Sweden.